Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Michael Bristow to Disease Progression

This is a "connection" page, showing publications Michael Bristow has written about Disease Progression.

 
Connection Strength
 
 
 
0.321
 
  1. Aleong RG, Sauer WH, Davis G, Bristow MR. New-onset atrial fibrillation predicts heart failure progression. Am J Med. 2014 Oct; 127(10):963-71.
    View in: PubMed
    Score: 0.071
  2. Le CH, Mulligan CM, Routh MA, Bouma GJ, Frye MA, Jeckel KM, Sparagna GC, Lynch JM, Moore RL, McCune SA, Bristow M, Zarini S, Murphy RC, Chicco AJ. Delta-6-desaturase links polyunsaturated fatty acid metabolism with phospholipid remodeling and disease progression in heart failure. Circ Heart Fail. 2014 Jan; 7(1):172-83.
    View in: PubMed
    Score: 0.068
  3. Bader FM, Gilbert EM, Mehta NA, Bristow MR. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail. 2010 Nov-Dec; 16(6):265-70.
    View in: PubMed
    Score: 0.055
  4. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005 May 31; 111(21):2837-49.
    View in: PubMed
    Score: 0.038
  5. Abraham WT, Gilbert EM, Lowes BD, Minobe WA, Larrabee P, Roden RL, Dutcher D, Sederberg J, Lindenfeld JA, Wolfel EE, Shakar SF, Ferguson D, Volkman K, Linseman JV, Quaife RA, Robertson AD, Bristow MR. Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med. 2002 Nov; 8(11):750-60.
    View in: PubMed
    Score: 0.032
  6. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet. 1998 Aug; 352 Suppl 1:SI8-14.
    View in: PubMed
    Score: 0.024
  7. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003 Sep 03; 42(5):914-22.
    View in: PubMed
    Score: 0.008
  8. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol. 2001 May; 37(6):1692-9.
    View in: PubMed
    Score: 0.007
  9. Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ, Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001 Apr; 107(8):967-74.
    View in: PubMed
    Score: 0.007
  10. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996 Dec 01; 94(11):2800-6.
    View in: PubMed
    Score: 0.005
  11. Cleland JG, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J. 1996 Nov; 17(11):1629-39.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)